key: cord-0732027-vougd8tf
authors: Rao, Guduru Gopal; Khanna, Priya
title: To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate
date: 2020-07-13
journal: Ther Adv Infect Dis
DOI: 10.1177/2049936120942424
sha: 2754417d4d5968ec32e9632160ba166c0ccf404c
doc_id: 732027
cord_uid: vougd8tf

Streptococcus agalactiae, also known as Group B streptococcus (GBS) is the commonest cause of early onset sepsis in newborns in developed high-income countries. Intrapartum antimicrobial (antibiotic) prophylaxis (IAP) is recognized to be highly effective in preventing early onset Group B sepsis (EOGBS) in newborns. The key controversy is about the strategy that should be used to identify mothers who should receive IAP. There are two strategies that are followed in developed countries: screening-based or risk-factor-based identification of women requiring IAP. The debate regarding which of the two approaches is better has intensified in the recent years with concerns about antimicrobial resistance, effect on newborn’s microbiome and other adverse effects. In this review, we have discussed some of the key research papers published in the period 2015–2019 that have addressed the relative merits and disadvantages of screening versus risk-factor-based identification of women requiring IAP. Although screening-based IAP appears to be more efficacious than risk-based IAP, IAP-based prevention has several limitations including ineffectiveness in prevention of late-onset GBS infection in babies, premature and still births, impact of IAP on neonatal microbiota, emergence of antimicrobial resistance and difficulties in implementing IAP-based strategies in middle and low income countries. Alternative strategies, principally maternal immunization against GBS would circumvent use of IAP. However, no licensed vaccines are currently available for use.

About 15-30% of pregnant women are colonised with Group B streptococcus (GBS) in the genital and gastrointestinal tract. Of the babies born to GBS colonised women, half of the babies will get colonised with GBS. Two-thirds of invasive infections occur in 0-6 days of life [early-onset GBS infections (EOGBS)] and a third occur within 7-90 days after birth [late-onset GBS infections (LOGBS)]. 1 Pneumonia, septicaemia and meningitis are the commonest invasive infections. A paper by Schuchat in 1998 on the pattern of GBS infection in the neonate before the universal adoption of screening in the United States (US) reported that 30% occurred in preterm babies, and 70% in otherwise healthy term babies. 2 In developed countries where intrapartum prophylaxis is used for prevention, the relative proportion of EOGBS and LOGBS is changing. In the United Kingdom (UK), a recent survey in 2014-2015 when compared with a similar survey in 2000, showed that the proportion EOGBS fell from 66.4% in 2000 to 60.4% in 2014-2015. During the same period, LOGBS increased from 33.6% in 2000 to 39.6% in 2014-2015. 3 Similarly, the rate of LOGBS infection (0.31/1000 live births) is higher than EOGBS infection (0.23/1000 live births) in the US.

The falling incidence of early versus late onset disease is usually attributed to prevention of early onset disease by intrapartum antibiotic To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate prophylaxis and the absence of such an effect on late onset disease. 4 It is estimated that worldwide about 22 million women carry GBS with an estimated 410,000 infections in newborns every year, with at least 147,000 still births and infant deaths globally.

Furthermore, the same study estimated that there were 33,000 cases of invasive GBS disease in pregnant or postpartum women, and 57,000 foetal infections/stillbirths. Up to 3.5 million preterm births may be attributable to GBS. 5 Currently, it is widely agreed that the only effective way to prevent EOGBS is to give intrapartum antibiotic prophylaxis (IAP) to the mothers. IAP has an efficacy of >80% in prevention of EOGBS. 6 However, there is considerable disagreement and debate about the best way of identifying women who need IAP. 7 In tandem, there is an emerging debate regarding the impact of IAP on the microbiome of the newborn. 8 In this article, we discuss some of the key research papers published in the period 2015-2019 that have addressed the relative merits and disadvantages of screening versus risk-factor-based strategies for identification of women requiring IAP. Where older papers are cited, it was done to set the context for more recent papers. Importantly, the papers were selected to provide a general overview of the debate rather than to undertake a systematic review or in-depth discussion of the components or variations of the two strategies. We have also excluded systematic reviews or studies based on meta-analysis of trials. Discussion regarding vaccines for prevention of EOGBS and effect of IAP on the neonatal microbiome is outside the scope of this paper.

Until recently there was no review of EOGBS prevention strategies used worldwide. A recent paper has addressed this gap in knowledge. Le Doare et al. reviewed GBS screening policies and IAP implementation worldwide. 9 They received policy information from nearly half the countries surveyed [95 of 195 (49%)]. Of these, over 60% had an IAP policy; a majority used screening (58%) while the rest used the presence of risk factors to guide IAP. Coverage was considerably higher with screening (80%) compared with riskfactor-based IAP (29%). The authors concluded that there was considerable heterogeneity in IAP screening policies and coverage worldwide. Screening-based guidelines used in many parts of the world are derived from EOGBS Prevention Guidelines recommended by Centers for Disease Control in the US (CDC) While the guidelines primarily recommend IAP based on antenatal GBS screening, they also recommend giving IAP to women with risk factors such as GBS bacteriuria during pregnancy or a history of a previous GBS-infected newborn. In addition, CDC recommends that if the prenatal GBS culture result is unknown when labour starts, intrapartum antibiotic prophylaxis is indicated for women who have risk factors for GBS early onset disease (EOD). These include at-risk women who present in labour with a substantial risk of preterm birth, who have preterm prelabour rupture of membranes (PPROM) or rupture of membranes for 18 or more hours at term, or who present with intrapartum fever [temperature 100.4°F (38°C) or higher. 10 Thus the CDC guidelines recommend a 'combined' approach with emphasis on screening.

CDC guidelines state that the culture method is the gold standard for identifying GBS. The guidelines also recommend using selective enrichment broth prior to culturing on solid agar media. Cultures can take up to 48 to 72 h and therefore can be done only during the antenatal period. It is now well recognised that antenatal cultures do not accurately predict intrapartum GBS carriage.

In the past decade, the availability of rapid nucleic acid amplification tests (NAATs) with very high specificity and sensitivity has made it possible to test women at the beginning of labour (intrapartum) with results available within a couple of hours. 11 This is particularly useful for testing women who have not been previously screened or who present in pre-term labour. However, NAATs require expensive equipment and reagents that may not be available in resource poor countries. The biggest disadvantage of NAATs is that they do not provide information regarding antibiotic susceptibility of the GBS strains, which is important for deciding the antibiotic treatment options in penicillin allergic women and surveillance of antimicrobial resistance. journals.sagepub.com/home/tai 3

To this day, there are no randomised controlled trials to compare the efficacy of the two strategies.

Recently, the National Institute of Health Research (NIHR) commissioned a cluster randomized trial in the UK to compare the effectiveness of the two strategies. The NIHR-funded study (GBS-3 Trial) will measure the effectiveness of two tests to identify group B streptococcus in late pregnancy or labour compared with the current UK approach of identifying pregnant women with 'risk factors' for their newborn developing the infection. The trial will include over 80 hospitals in the UK. The trial was due to commence in April 2020 but recruitment has been delayed due to the Covid 19 pandemic (https://www.nihr.ac.uk/news/newscreening-trial-aims-to-improve-detection-andtreatment-for-group-b-strep-in-pregnant-women/ 20283 accessed 03-05-2020).

In the absence of randomised trials, virtually all the reports published thus far are based on observational 'before-after' studies. The following are a brief description of some of the studies published recently.

In Germany, the national guidelines changed from risk factor based IAP ( The annual incidence in 2015 and 2016 was significantly higher than in any previous year (p < 0.0001), coinciding with the discontinuation of routine universal maternal GBS screening. They found that neonates of unscreened mothers were more likely to present with EOD (p = 0.005). They concluded that incidence of neonatal GBS infection in Saudi Arabia is similar to the worldwide incidence. Importantly, like Rao et al., they observed that discontinuation of universal antenatal screening was significantly associated with an increase in EOGBS incidence. 19 While Africa has the highest burden of EOGBS infection in the world, there are continuing challenges in implementing intrapartum prophylaxis, both using risk-based or screening-based strategies due to limited resources. 20 It is clear that only vaccines can provide a realistic solution for prevention of GBS related infant mortality in most parts of Africa. Maternal GBS vaccination could be a safe, cost-effective strategy and prevent 30-55% deaths in low-income sub-Saharan Africa. 21 In summary, many observational studies appear to find a screening-based strategy more efficacious in preventing EOGBS than a risk-based strategy. However, experience in New Zealand suggests that risk-based strategy can be effective, 12 although in the UK, the EOGBS rates have gone up despite the introduction of risk-based strategy in 2003. 13 Adverse effects Today the principal debate regarding the relative merits of the two strategies has shifted from efficacy to adverse effects of IAP. While both strategies offer IAP to mothers, it is argued that a screening-based strategy exposes more mothers to antibiotics than risk-based strategy and as a result, are more likely to suffer adverse effects. 22 Does screening-based strategy lead to more women getting IAP than with a risk-based strategy?

A key modelling study based on primary data by Kaambwa et al. showed that a similar number of patients would receive antibiotics using either strategy. Of the 1400 women recruited into the study, 22.1% women had risk factors whereas journals.sagepub.com/home/tai 5 21% screened women were GBS carriers. The sensitivity and specificity of risk-based IAP were 31% and 80%, respectively, compared with antenatal screening cultures which had sensitivity and specificity of 76% and 95%, respectively. These findings indicate that just as many women would receive IAP with both strategies but using a riskbased strategy, IAP would be unnecessarily given to 69% of women who are not GBS carriers. Furthermore, the authors concluded that riskbased IAP was not cost effective. 23 Turning to adverse effects, Seedat et al. observed in a systematic review that despite a wide range of adverse events occurring following IAP, the evidence was inconsistent and at high risk of bias. Seven observational studies showed that IAP for maternal GBS colonization altered the infant microbiome but significance of these changes on clinical outcomes was not described and, as such, the importance of these alterations is unclear. The authors noted there was also observational evidence for increased antimicrobial resistance; however, studies were at high or unclear risk of bias. 22 Millions of doses of penicillin or ampicillin have been given as IAP clinically significant resistance to penicillin or ampicillin has not been reported. Although penicillin-resistant GBS have been reported in respiratory isolates from patients in Japan, they were not detected in GBS strains isolated from mothers or their babies. 26 Recently however, Moroi et al. determined the minimum inhibitory concentration of seven β-lactam antibiotics for 477 GBS isolates derived from vaginal/ rectal swabs from pregnant women. All the 477 isolates were susceptible to penicillin G and ampicillin. Five isolates showed reduced ceftibuten susceptibility. Each of these isolates possessed a single amino acid substitution in the penicillin binding protein, PBP2X, and some of the substitutions which had been previously found in GBS strains with reduced penicillin susceptibility. It is unclear if this will eventually lead to penicillin resistance in GBS. 27 A major concern has been that IAP increases the risk of anaphylactic reaction to penicillin. To date, there have been very few confirmed reports of anaphylaxis in women who received penicillin or ampicillin as IAP. In this context, a recent study by McCall et al. is important. 28 They estimated the incidence of anaphylaxis in pregnancy and described the management and outcomes in the UK using the UK Obstetric Surveillance System. All pregnant women who had anaphylaxis between 1 October 2012 and 30 September 2015 were included. There were 37 confirmed cases of anaphylaxis in pregnancy but only one due to IAP given for prevention of EOGBS. This anaphylactic reaction did not prove to be fatal for the mother or the baby. The authors concluded that the overall low incidence was reassuring given the large proportion of the pregnant population that receive prophylactic antibiotics during delivery.

Overall, we believe that screening-based IAP is more efficacious than risk-based IAP and is the preferred option in developed countries. Rapid availability of results using NAATs may enable use of these tests to accurately target IAP to GBS colonized women in the intrapartum period. At a practical level, there are major challenges in implementing screening-based IAP in low income countries with poor laboratory support. In these countries, clinical risk-based IAP may be preferable albeit with lower efficacy. It must be acknowledged that IAP-based prevention has many limitations. IAP is not effective in prevention of late-onset GBS infection in babies, premature deliveries and still births due to GBS infection. There are also growing concerns regarding the possible impact of IAP on neonatal microbiota and emergence of antimicrobial resistance. While resistance to clindamycin has risen considerably in the recent years, GBS strains from pregnant women have remained susceptible to penicillin. Reassuringly, a recent study from the UK has shown that anaphylactic reaction to penicillin is very rare in women who received IAP.

Alternative strategies, principally maternal immunization against GBS would avoid use of IAP. A recent modelling study estimated that a maternal vaccine with 80% efficacy and 90% coverage could prevent 107,000 (Uncertainty Range, 20,000-198,000) stillbirths and infant deaths. 5 Unfortunately, no vaccines are currently available for routine use. Until such time vaccines are available, IAP-based prevention of EOGBS is the only game in town!

GGR and PK contributed equally to writing and reviewing the final manuscript.

GR is a member of medical advisory committee of the charity, Group B Streptococcus Support (GBSS)

Neonatal infections: group B streptococcus

Epidemiology of group B streptococcal disease in the United States: shifting paradigms

Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study

Epidemiology of invasive early-onset and lateonset group B streptococcal disease in the United States

Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children

Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease

Universal antenatal screening for group B streptococcus may cause more harm than good

Maternal group B Streptococcus and the infant gut microbiota

Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review

ACOG COMMITTEE OPINION Committee on Obstetric Practice. Early-onset Group B streptococcal disease

Realtime PCR assay provides reliable assessment of intrapartum carriage of group B Streptococcus

Group B streptococci: declining incidence in infants in Germany

Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States

Outcome of a screening programme for the prevention of neonatal invasive early-onset group B Streptococcus infection in a UK maternity unit: an observational study

Early-onset group B Streptococcus (EOGBS) infection subsequent to cessation of screeningbased intrapartum prophylaxis: findings of an observational study in West London

Group B streptococcal screening, intrapartum antibiotic prophylaxis, and neonatal early-onset infection rates in an Australian local health district

Earlyonset neonatal group B streptococcus sepsis following national risk-based prevention guidelines

Prevention of early onset group B streptococcal disease by universal antenatal culture-based screening in all public hospitals in Hong Kong

Neonatal group B streptococcal infection in a tertiary care hospital in Saudi Arabia

Challenges in reducing group B Streptococcus disease in African settings

Costeffectiveness of maternal GBS immunization in low-income sub-Saharan Africa

Adverse events in women and children who have received intrapartum antibiotic prophylaxis treatment: a systematic review

Costeffectiveness of rapid tests and other existing strategies for screening and management of earlyonset group B streptococcus during labour

Modelling the effect of the introduction of antenatal screening for group B Streptococcus (GBS) carriage in the UK

Institution of universal screening for Group B streptococcus (GBS) from a risk management protocol results in reduction of early-onset GBS disease in a tertiary obstetric unit

High isolation rate of MDR group B streptococci with reduced penicillin susceptibility in Japan

Isolation of group B Streptococcus with reduced β -lactam susceptibility from pregnant women

The incidence, characteristics, management and outcomes of anaphylaxis in pregnancy: a population-based descriptive study

The authors received no financial support for the research, authorship, and/or publication of this article.

Guduru Gopal Rao https://orcid.org/0000-0002-8108-4431